Bicara therapeutics to present updated data from ongoing phase 1/1b trial of ficerafusp alfa in 1l r/m hnscc at the 2025 american society of clinical oncology (asco) annual meeting

Boston, april 23, 2025 (globe newswire) -- bicara therapeutics inc. (nasdaq: bcax), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that updated data from the company's ongoing phase 1/1b clinical trial of ficerafusp alfa in 1l (first line) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (hnscc) will be highlighted in an oral presentation at the 2025 american society of clinical oncology (asco) annual meeting, which will be held from may 30-june 3, 2025 in chicago, il. ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (egfr) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (tgf-Β) and is being evaluated across multiple solid tumor types.
BCAX Ratings Summary
BCAX Quant Ranking